Author of

• 35693

  +

  P52 - Staging - Prognosis and Staging (ID 186)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Staging
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 35706

    +

    P52.11 - Prognostic Positioning of EGFR Mutated Advanced Lung Cancer in Relation to the Treatment Modalities (ID 2522)

    00:00 - 00:00  |  Presenting Author(s): Won-Il Choi
    • Abstract

    Introduction
    

    The treatment of epidermal growth factor receptor (EGFR)-mutated lung cancer cases has shown remarkable development in the past two decades. However, there have been limited studies comparing prognostic effect of EGFR tyrosine kinase inhibitor (TKI) and other treatment modalities. Therefore, we set to compare the survival outcomes in patients treated with EGFR TKIs versus those treated with other treatment modalities.

    Methods
    

    Patient data were collected from the Korean National Health Insurance Database, NHIS-NSC 2002-2015, which was released by the Korean National Health Insurance Service (KNHIS) in 2015. The Lung cancer group included patients (N=2003) initially diagnosed with lung cancer between January 2010 and December 2013. The main outcome was all-cause mortality. A Cox proportional hazard regression analyses was used to calculate the relative risk of mortality

    Results
    

    Among the newly diagnosed lung cancer cases, 1004 (50.1%) were included for the analysis. A 15.1 months median survival benefit was observed in the EGFR TKI group than in the multimodality therapy group. Further, the risk of mortality was as follows: EGFR TKI treatment group (n = 142; HR: 5.29; 95% CI: 3.57-7.86) and multimodality therapy group (n = 326; HR: 7.42; 95% CI: 5.19-10.63) compared to surgery only (n = 275).

    Conclusion
    

    Patients with advanced lung cancer harbouring EGFR mutations treated with EGFR-TKIs showed better median survival and low risk of mortality than those in the multimodality therapy group. Moreover, EGFR-TKI therapy can be considered to down-stage EGFR-mutant tumours in TNM classification.